CERo Therapeutics Hldgsの空売り状況は、投資家がCERo Therapeutics Hldgsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

CERo Therapeutics Hldgs (NASDAQ:CERO) 株価情報, 空売り情報

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

WIIM

AGFY

Agrify shares are trading higher after the company reported a year-over-year increase in Q3 EPS results.

Analyst Ratings

SBUM

CORRECTION: RBC Capital analyst Logan Reich assumes Starbucks (NASDAQ: SBUX) with a Outperform rating and announces Price Target of $115.

CORRECTION: RBC Capital analyst Logan Reich assumes Chipotle Mexican Grill (NYSE: CMG) with a Outperform rating and announces Price Target of $70.

SeaStar Medical shares are trading higher after the company announced the shipment of its 100th QUELIMMUNE commercial device to its third hospital customer.

Vireo Growth Inc., formerly known as Goodness Growth Holdings, (CSE:<a class="ticker" href="https://www.benzinga.com/stock/VREO#CSE">VREO</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VREOF#OTCQX">VREOF</a>) reported on Wednesday financial results for its third quarter ended Sept. 30, 2024.
"Our third quarter results reflect continued solid performance across our core markets, but as we discussed anticipating last quarter, year-over-year comparisons of financial performance are less significant now that we have passed the one-year anniversary of the launch of adult-use sales in Maryland," CEO Amber Shimpa said. "Our teams continue to focus on preparing for the launch of adult-use sales in Minnesota next year, and our recently announced $10.0 million financing commitment gives us additional flexibility to support this launch and continue executing our CREAM &amp; Fire strategy."
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40207055/vireo-growth-inc-turns-1m-loss-into-5-8m-gain-in-q2-what-investors-need-to-know-about-this-canna">Vireo Growth Inc. Turns $1M Loss Into $5.8M Gain In Q2: What Investors Need To Know About This Cannabis Stock</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Revenue increased by 2% year-over-year to $25.2 million</li>
<li>Revenue, excluding discontinued operations and the New York market, was up 6.2% year-over-year.</li>
<li>Gross profit decreased by 6.6% year-over-year, reaching $12.3 million, with a gross margin of 49%, down from 53.5% in the prior year's quarter.</li>
<li>Operating income was $3.9 million, down 34.4% compared to the previous year's third quarter.</li>
<li>EBITDA dropped 19.4% to $5.7 million.</li>
<li>Selling, general and administrative expenses increased by 2.4% year-over-year.</li>
<li>Retail revenue grew 2% year-over-year and wholesale revenue saw a 24.4% increase over the same period.</li>
<li>Vireo&#8217;s operations in Maryland and Minnesota showed mixed results with Maryland achieving 12.1% year-over-year growth, while Minnesota saw a slight decline.</li>
</ul>
In November, Vireo secured a new $10 million convertible debt facility to support its upcoming adult-use sales launch in Minnesota and continued operations.
<h3 class="wp-block-heading">VREOF Price Action</h3>
Vireo's shares traded 5.15% lower at 4 cents per share after the market close on Thursday afternoon.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40131513/vireo-growth-extends-credit-facility-with-chicago-atlantic-its-not-been-an-easy-path-for-us-says">Vireo Growth Extends Credit Facility With Chicago Atlantic: &#8216;It&#8217;s Not Been An Easy Path For Us&#8217; Says CEO</a></li>
</ul>

Cannabis

Earnings

News

CSE:VREO

VREOF

Cannabis Co. Vireo Reports 2% YoY Revenue Growth, Secures $10M In Financing

MRKR

Marker Therapeutics shares are trading lower. The company reported Q3 financial results.

TTOO

T2 Biosystems shares are trading lower after the company reported worse-than-expected Q3 revenue results.

VEEE

Twin Vee PowerCats shares are trading lower. The stock may be moving on continued weakness following a year-over-year Q3 revenue decline reported on Thursday.

California cannabis company Lowell Farms Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LOWLF#OTCQX">LOWLF</a>) announced its unaudited revenue and operating results Thursday for the third quarter of 2024, reporting net revenue of $3.2 million, down 48% from $6.2 million in the same period last year. Net revenue decreased by 8% from $3.5 million in the second quarter of 2024.
"We're happy to share the progress Lowell Farms made towards expanding our footprint into the California retail market," stated co-founder and CEO Mark Ainsworth. "This strategic move marks a new chapter for us, enabling us to further showcase the strength of our brand portfolio, now in our own retail spaces and deliver an enhanced customer experience. As we focus on strategic, selective growth, we're confident that this expansion will solidify Lowell's position in the market, bringing us closer to our vision for sustainable and meaningful growth."
Read Also: <a href="https://www.benzinga.com/24/11/41982261/im-cannabis-achieves-66-revenue-growth-in-germany-narrows-ebitda-loss-in-q3">IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Q3 Financial Highlights</h2>
<ul>
<li>CPG revenue decreased 26% compared to the same quarter of 2023.</li>
<li>Bulk product revenue from self-grown wholesale products was $nil million compared to $1.2 million for the quarter ended Sept. 30, 2023, reflecting our exit from the cultivation facility in January 2024.</li>
<li>Gross margin was negative 29.0% representing a gross loss of $900,000, reflecting the sell through of higher cost inventory associated with the cultivation facility which adversely impacted cost of goods sold by $600,000 in the third quarter.</li>
<li>Operating loss was $2.8 million, compared to operating loss of $2.9 million for the same period last year.</li>
<li>Net loss was $3.6 million compared to a net loss of $20.2 million for the comparable period of 2023.</li>
<li>Adjusted EBITDA was negative $2.1 million compared to adjusted EBITDA of negative $1.4 million for the third quarter last year.</li>
</ul>
<h2 class="wp-block-heading">Price Action</h2>
Lowell Farms shares closed Thursday's market session flat at $0.015 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41974843/cbd-pharma-co-medipharm-37-increase-in-q3-international-sales-15-yoy-revenue-growth">CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth</a> 

</li>
</ul>
Photo: Courtesy of YARphotographer via Shutterstock

LOWLF

California Cannabis Company Lowell Farms Reports 48% YoY Revenue Decline In Q3

<a href="https://www.globenewswire.com/Tracker?data=TasyziQV3sWM0A4NpDTDXXuoGzlj19faWYDgmgak5zdeB0NwGr7ExJHPjJx-Yk3xdZyZlmGcFLHgW-Xo4jWMwJ5-GZr_WKDNiItVThueFOE=">Red Cat Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) ("Red Cat"), a drone technology company building hardware and software for military, government, and commercial operations, today announced that it will hold a Town Hall Meeting for investors, analysts and members of the media on Tuesday, November 19, 2024.
Company management will provide an update on new developments for Black Widow&#x2122;, which the company introduced as part of its ARACHNID&#x2122; Family of Small ISR and Precision Strike Systems at AUSA 2024. Following management's formal remarks, there will be a question-and-answer session.

Events

RCAT

Red Cat Announces It Will Hold A Town Hall Meeting For Investors, Analysts And Members Of The Media On Tuesday, November 19, 2024; Will Provide An Update On New Developments For Black Widow

MAMO

Massimo Group shares are trading lower after the company reported a year-over-year decrease in Q3 financial results.

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending Nov. 15:
Axon Enterprises Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>): The weapons and cloud-based digital evidence company was one of many that<a href="https://www.benzinga.com/news/large-cap/24/11/41886058/donald-trump-victory-week-nov-4-8-these-large-cap-stocks-were-biggest-gainers"> saw strong interest </a>from investors after the 2024 presidential election was won by Donald Trump. 
The company recently reported third-quarter revenue of $544.3 million, up 32% year-over-year. The revenue total beat a Street consensus estimate of $525.1 million. Axon also reported earnings per share of $1.45, which beat a Street estimate of $1.20. 
The quarter continued a streak of consecutive quarters of beating analyst estimates, which now stands at 10 for both revenue and earnings per share. Axon also shared revenue guidance for the fourth quarter with an expected range of $560 million to $570 million, ahead of a Street estimate of $523 million. 
Analysts <a href="https://www.benzinga.com/quote/AXON/analyst-ratings">raised price targets</a> on Axon after the earnings and 2024 election. Northland maintained an Outperform rating and raised the price target from $365 to $550, Needham maintained a Buy rating and raised the price target from $525 to $600 and Baird maintained an Outperform rating and raised the price target from $460 to $600.
Axon shares were up over 11% over the last five days, as of writing. The stock is up over 140% year-to-date in 2024. The Axon <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> is below.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241.png" alt="" class="wp-image-650644" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241-768x375.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>): The cloud and data company is seeing increased interest ahead of third-quarter financial results. The company will report third-quarter results after market close on Nov. 20. Analysts expect the company to report earnings per share of 15 cents, down from 25 cents and revenue of $897.6 million, up from $734.2 million. 
The company has beaten analyst estimates for earnings per share in nine of the past 10 quarters and for revenue in more than 10 straight quarters. 
Snowflake's second-quarter revenue was up 29% year-over-year with product revenue up 30% year-over-year and the company's net revenue retention rate at 127% in the quarter. Snowflake reported remaining performance obligations of $5.2 billion and a total of 510 customers.
"With the combination of our platform, the network effect of collaboration and our AI innovations, we have a huge opportunity ahead to deliver even greater value to deliver even greater value to our customers," Snowflake CEO Sridhar Ramaswamy said after<a href="https://www.benzinga.com/news/earnings/24/08/40494892/snowflake-q2-earnings-revenue-beat-eps-beat-raised-guidance-additional-2-5b-buyback-great-traction-"> second-quarter results.</a>
With cybersecurity a key theme moving forward <a href="https://www.benzinga.com/24/11/41849944/financial-crime-weekly-alleged-snowflake-hacker-arrested-banned-china-chip-shipments-payday-advance-company-sued">and recent hacks,</a> Snowflake stock could continue to see interest from investors. Snowflake stock was up around 5% over the last week, but shares are down more than 30% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242.png" alt="" class="wp-image-650645" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242-768x386.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>): The electrical and manufacturing construction and facilities services provider is <a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">back on the Stock Whisper Index</a>. 
The company recently reported third-quarter financial results with earnings per share beating analyst estimates and revenue missing estimates. Guidance from the company was similar with full-year revenue guidance of revenue set at $14.5 billion, down from a prior range of $14.5 billion to $15.0 billion and below a Street estimate of $14.7 billion. 
EMCOR expects full-year earnings per share of $20.50 to $21, up from a previous range of $19 to $20 and ahead of a Street estimate of $19.53 per share. The stock could benefit from interest rate cuts and the administration. 
Stifel <a href="https://www.benzinga.com/quote/EME/analyst-ratings">recently initiated </a>the stock with a Buy rating and $600 price target. The stock was up after the 2024 election before cooling off in the past week. Shares were down on the week, but remain up over 130% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243.png" alt="" class="wp-image-650647" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243-768x375.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>): The space and rocket company continues to see strong interest from readers. The company reported<a href="https://www.benzinga.com/general/space/24/11/41922070/rocket-lab-q3-earnings-revenue-beat-eps-beat-continued-strong-demand-growth-multi-launch-agreement-air-force-award-and-more"> third-quarter financial results</a> recently with revenue of $104.8 million and earnings per share of a loss of 10 cents per share both beating analyst estimates. 
Rocket Lab's revenue was up 55% year-over-year in the quarter. The company has already passed a new annual launch record with 12 Electron launches so far, with more scheduled in November and December. Rocket Lab highlighted its backlog of over $1 billion and strong demand growth in the quarterly results.
"We expect to close out the year strongly with more Electron launches scheduled in November and December, alongside continued progress across Neutron and space systems, that is behind our guidance for a record $125-$135 million revenue quarter in Q4," Rocket Lab CEO Peter Beck said.
The company also announced a multi-launch agreement with an unnamed commercial satellite company and an award from the U.S. Air Force Research Laboratory worth up to $8 million.
Beck highlighted the company's backlog including over 40 spacecraft that range from missions to Mars, national security and telecommunications projects for partners during an <a href="https://www.benzinga.com/general/space/24/11/41961309/rocket-lab-ceo-touts-spacex-rival-status-trump-impact-on-space-as-stock-surges-almost-30">interview on CNBC. </a>Beck also expressed optimism about space policy under incoming President Donald Trump.
Analysts <a href="https://www.benzinga.com/quote/RKLB/analyst-ratings">raised their price targets</a> on Rocket Lab after the quarterly financial results. The stock was up 30% over the past five days and is up over 225% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="485" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244.png" alt="" class="wp-image-650648" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244-768x372.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
The Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>): The advertising company saw strong interest from readers after reporting<a href="https://www.benzinga.com/news/earnings/24/11/41830188/the-trade-desk-stock-is-tumbling-after-the-bell-whats-going-on"> third-quarter financial results.</a> Third-quarter earnings per share of 41 cents beat a street estimate of 39 cents per share and revenue of $628.0 million beat a Street estimate of $620 million. 
The company has now beaten analyst estimates for earnings per share in nine of the past 10 quarters and beaten revenue estimates in more than 10 straight quarters. Trade Desk said its customer retention was over 95% in the quarter.
"As we enter our busiest time of year and look ahead to 2025, we have never been in a better position to capture a greater share of the $1 trillion advertising TAM," The Trade Desk CEO Jeff Green said.
Trade Desk's guidance for the fourth quarter came in ahead of Street estimates for revenue. Several analysts <a href="https://www.benzinga.com/quote/TTD/analyst-ratings">raised their price targets </a>on the stock after the quarterly results.
Trade Desk shares were down 5.11% over the past five days and the stock is up 78% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245.png" alt="" class="wp-image-650649" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245-768x384.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 25</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/11/41693907/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">November 1</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">November 8</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/24/11/41779731/trump-victory-sends-bank-stocks-higher-leading-s-p-500-on-regulatory-hopes" target="_blank" rel="noreferrer noopener">Trump Victory Sends Bank Stocks Higher, Leading S&amp;P 500 On Regulatory Hopes</a></li>
</ul>

SPACE

Exclusives

Trading Ideas

AXON

RKLB

SNOW

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

ATXI

Avenue Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results

Offerings

On Thursday November 14, 2024, Red Cat Holdings Filed For $100M Mixed Securities Shelf

Starbucks's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>) short percent of float has fallen 11.2% since its last report. The company recently reported that it has 25.17 million shares sold short, which is 2.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Starbucks Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731689169_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Starbucks has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Starbucks's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Starbucks's peer group average for short interest as a percentage of float is 10.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SBUX

(SBUX) - Analyzing Starbucks's Short Interest

Selective Insurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NYSE">SIGI</a>) short percent of float has risen 4.28% since its last report. The company recently reported that it has 1.24 million shares sold short, which is 2.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Selective Insurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731689164_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Selective Insurance Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Selective Insurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Selective Insurance Gr's peer group average for short interest as a percentage of float is 1.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SIGI

Peering Into Selective Insurance Gr's Recent Short Interest

Inhibikase Therapeutics shares are trading lower. The stock may be moving on continued weakness after reporting worse-than-expected Q3 EPS results yesterday.

Element Solutions's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) short percent of float has risen 4.05% since its last report. The company recently reported that it has 1.72 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Element Solutions Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731689158_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Element Solutions has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Element Solutions's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Element Solutions's peer group average for short interest as a percentage of float is 3.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Element Solutions?

Student loan policies could be overhauled under President-elect Donald Trump&#8217;s upcoming administration, with several existing programs likely to undergo changes or be eliminated.
The Biden administration&#8217;s Saving on a Valuable Education (SAVE) repayment plan, currently serving eight million borrowers, stands at a crossroads. The program&#8217;s fate hangs in the balance as the 8th Circuit Court of Appeals weighs its legality, with no clear indication that Trump&#8217;s administration would continue defending it.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
</ul>
&#8220;The reason [the Biden] administration is defending the rule so vigorously is it was providing a much more affordable repayment plan,&#8221; Persis Yu, deputy executive director at Student Borrower Protection Center, told CNBC Make It last week.
Trump&#8217;s previous term offers insights into potential policy directions. According to CNBC, his administration proposed eliminating Public Service Loan Forgiveness and slashed funding for various higher education programs. During that period, roughly 99% of PSLF applicants faced rejection by 2019, leading to legal action from teachers&#8217; unions against then-Secretary of Education Betsy DeVos.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
The administration&#8217;s approach to borrower protections also shifted. Rules were loosened for institutions to demonstrate student success outcomes, resulting in an estimated $11 billion reduction in debt relief for borrowers affected by questionable academic programs, particularly at for-profit colleges.
Project 2025, a policy agenda developed by The Heritage Foundation, outlines more dramatic changes. While <a href="https://www.benzinga.com/news/24/07/39874558/trump-disassociates-himself-from-extreme-project-2025-at-michigan-rally-i-dont-know-what-the-hell-it">Trump has distanced himself from the proposals</a>, the agenda calls for eliminating PSLF and borrower defense programs. More importantly, it proposes dismantling the Department of Education and returning to private lender dominance in education financing.
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
The shift toward private lending raises concerns among borrower advocates. &#8220;What kind of corporate interests are going to be protected over the interests of borrowers and students,&#8221; Yu said to CNBC. Private student loans typically carry higher costs as lenders set interest rates independently, unlike federal loans, where Congress determines rates.
The transition could leave millions of borrowers in limbo regarding their monthly payments. Biden&#8217;s alternative debt relief plan, targeting long-term borrowers and those from low-value academic programs, faces legal challenges that the Trump administration appears unlikely to defend against Republican-led lawsuits.
See Also: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
The landscape marks a pivot from March 2020, when <a href="https://www.benzinga.com/government/24/09/40780284/student-loan-protection-soon-ends-9-7m-borrowers-should-be-worried-about-their-credit-ratings">Trump initiated the pandemic-related payment pause</a>. That policy lasted throughout his term and provided widespread relief to federal loan borrowers. His return to office signals a potentially different approach to student debt management, emphasizing private sector solutions over federal programs.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Personal Finance

Is Trump's Second Term Going To Affect Student Loan Borrowers? Here Are 3 Potential Changes

CELC

Celcuity shares are trading lower after the company reported worse-than-expected Q3 EPS results.

CERo Therapeutics Holdings ( ($CERO) ) has issued an update. CERo Therapeutics Holdings, Inc. has secured $1.25 million through a private placement...

CERo Therapeutics' Strategic Moves Amidst Leadership Change

CERo Therapeutics Holdings ( ($CERO) ) has shared an update. CERo Therapeutics Holdings, Inc. has strategically bolstered its leadership with the a...

CERo Therapeutics Enhances Leadership for Clinical Advancements

CERo Therapeutics gets new finance head

CERo Therapeutics Holdings ( ($CERO) ) has issued an update. Shami Patel, a seasoned financial expert with over 25 years of experience, has been ap...

CERo Therapeutics Welcomes Shami Patel to Board After Resignation

CERo Therapeutics (CERO) provides the following corporate update to stockholders from Interim CEO Chris Ehrlich, "Following the events of the last ...

Cero Therapeutics submits IND clinical hold CRL to the FDA

16:44 EDT Cero Therapeutics (CERO) files to sell 713.56M shares of common stock for holders Published first on TheFly – the ultimate source for rea...

Cero Therapeutics files to sell 713.56M shares of common stock for holders

CERo Therapeutics files to sell 713.6M shares of common stock for holders

CERo Therapeutics stock is rising higher on Monday as investors react to the latest preclinical data concerning lead compound CER-1236.

CERo Therapeutics' (CERO) Stock Sees Significant Climb After Revealing Ovarian Cancer Data

FOXO Technologies, CERo Therapeutics Holdings, and Mullen Automotive are the 3&nbsp;Penny Stocks&nbsp;to watch on November 14, 2024, based on&nbsp;...

3 Penny Stocks to Watch Now, 11/24/24

CERo Therapeutics (CERO) announces that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug Application for Ph...

Cero Therapeutics receives FDA clearance of IND application for CER-1236

CERO

FOXO

MULN

Press Releases

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

Health Care

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

GlycoMimetics

HOOKIPA Pharma

ImmuCell

IN8bio

MiNK Therapeutics

Kairos Pharma

Longeveron

Marker Therapeutics

Ocean Biomedical

Pluri

RenovoRx

SAB Biotherapeutics

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

CERo Therapeutics shares are trading higher after the company received FDA clearance for its investigational new drug application to initiate a Phase 1 clinical trial of CER-1236 for acute myelogenous leukemia.

Comments

CERo Therapeutics Hldgs

空売り

CERo Therapeutics Hldgs (NASDAQ:CERO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル